Elevance Health (NYSE:ELV) Stock Rating Raised to "Buy" at Wall Street Zen

Elevance Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Elevance Health from “Hold” to “Buy. The stock has a consensus “Moderate Buy” rating from analysts, with an average price target of $456.48.
  • Elevance reported quarterly EPS of $6.99, beating the $4.71 consensus estimate, while revenue of $50.44 billion also exceeded expectations.
  • Executives disclosed stock sales: CFO Mark Kaye sold 10,584 shares, and EVP Ratnakar Lavu sold 1,300 shares.
  • MarketBeat previews top five stocks to own in December.

Elevance Health (NYSE:ELV - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday, Wall Street Zen reports.

Several other research firms have also recently commented on ELV. Mizuho set a $490.00 price target on Elevance Health in a report on Friday, October 23rd. TD Cowen increased their target price on Elevance Health from $465.00 to $495.00 and gave the company a "buy" rating in a report on Friday, October 23rd. Robert W. Baird increased their target price on shares of Elevance Health from $393.00 to $406.00 and gave the company a "neutral" rating in a research report on Thursday, October 22nd. The Goldman Sachs Group reissued a "neutral" rating and issued a $451.00 price objective on shares of Elevance Health in a report on Friday, October 23rd. Finally, Guggenheim upped their price objective on Elevance Health from $460.00 to $485.00 and gave the company a "buy" rating in a research note on Thursday, October 22nd. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $456.48.

Get Our Latest Report on ELV

Elevance Health Stock Performance

ELV stock opened at $426.17 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68. Elevance Health has a 12-month low of $274.84 and a 12-month high of $450.69. The stock has a market capitalization of $92.08 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 1.97 and a beta of 0.63. The stock's 50 day simple moving average is $412.92 and its 200 day simple moving average is $373.58.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.71 by $2.28. The business had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. Elevance Health's revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.03 earnings per share. As a group, research analysts forecast that Elevance Health will post 29.16 earnings per share for the current fiscal year.

Insider Activity at Elevance Health

In other news, CFO Mark Kaye sold 10,584 shares of the firm's stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the sale, the chief financial officer owned 19,919 shares of the company's stock, valued at $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Ratnakar Lavu sold 1,300 shares of the firm's stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the sale, the executive vice president owned 14,849 shares in the company, valued at $6,533,560. This represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Elevance Health

A number of hedge funds have recently modified their holdings of ELV. Activest Wealth Management raised its holdings in Elevance Health by 146.2% in the 3rd quarter. Activest Wealth Management now owns 64 shares of the company's stock valued at $25,000 after buying an additional 38 shares during the period. Kilter Group LLC purchased a new position in Elevance Health during the second quarter worth about $28,000. WealthCollab LLC increased its position in shares of Elevance Health by 42.2% during the first quarter. WealthCollab LLC now owns 91 shares of the company's stock valued at $27,000 after acquiring an additional 27 shares during the last quarter. Elevation Wealth Partners LLC raised its stake in shares of Elevance Health by 600.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 105 shares of the company's stock valued at $41,000 after acquiring an additional 90 shares during the period. Finally, Tacita Capital Inc acquired a new stake in Elevance Health in the 2nd quarter valued at approximately $44,000. Institutional investors and hedge funds own 89.24% of the company's stock.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

  • Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
  • Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
  • Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
  • Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Elevance Health Company Profile

(Get Free Report)

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.

See Also

Analyst Recommendations for Elevance Health (NYSE:ELV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elevance Health Right Now?

Before you consider Elevance Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.

While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines